leisure time -WSS

leisure time

author：hotspot 2025-10-01 01:00:28 - browse：7887

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： CDC advisory group OKs chikungunya vaccine

WSS

A look at other Americans who have crossed into North Korea over the years

Lack of darker skin in textbooks, journals harms patients of color

'Vaccine

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

NEJM study measures Covid brain fog, impact on IQ

Color Health wants to make cancer screenings convenient

explore

leisure time

leisure time

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Beam, Prozac, "TechBio" and more

Malaria cases in Florida and Texas: Here’s what you need to know

Twill hunts for pharma partner to market its depression app

Peter Hotez and the public health issue of online harassment

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

In age of alternative facts, a scholarly course on calling out crap

Pfizer is about to make a big push in cancer. Will investors listen?

BioMarin wins approval for gene therapy to treat hemophilia A

US soldier in North Korean custody after crossing DMZ line

focus

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Elisabeth Bik tackles the widespread issue of research misconduct

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Using force crossed my mind when examining a defiant young patient

ER docs worry over extreme heat as a 'mass casualty event'

explore

entertainment

explore

hotspot